| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.8 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |